News

Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). Results from the four ongoing trials, all of which met their primary efficacy endpoint, will

QIDP status is granted to drugs which act against pathogens which have a high degree of unmet need in their treatment and are identified by Centre for Disease

New trials will investigate rivaroxaban, the most studied Factor Xa inhibitor, for the treatment of acute coronary syndrome (ACS), embolic stroke of undetermined source (ESUS) and peripheral artery

The double blind, placebo controlled Phase IIb dose ranging trial was conducted in specialized cardiovascular centres across Denmark and the Netherlands. In the trial, a total of 364

Decitabine for injection is a generic version of Japanese pharmaceutical firm Eisai’s Dacogen. The drug is used to treat patients with myelodysplastic syndromes (MDS) including previously treated and

Scheduled to be initiated within weeks, the dose ranging efficacy trial in an experimental Ebola virus disease model in non-human primates represents a major step towards understanding the

LCZ696 is a twice a day tablet being investigated for heart failure and is indicated to reduce the strain on the failing heart. The company said that LCZ696

In order to solve the problems with our healthcare systems, as well as the patients, we need to look at the healthy that benefit from over the counter

Copaxone is marketed for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). Multiple sclerosis is a chronic disease of the central nervous system (CNS) characterized by inflammation and neurodegeneration.